Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Zevra Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Zevra Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was 42.8%. For fiscal 2025 it was 78.2%, against -446.9% the year before. The highest annual figure on record is 78.2% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 78.2% | +525.0 |
| FY2024 | Dec 31, 2024 | -446.9% | −279.2 |
| FY2023 | Dec 31, 2023 | -167.7% | +95.8 |
| FY2022 | Dec 31, 2022 | -263.5% | −233.6 |
| FY2021 | Dec 31, 2021 | -29.9% | +66.2 |
| FY2020 | Dec 31, 2020 | -96.0% | +95.0 |
| FY2019 | Dec 31, 2019 | -191.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 22.1% | −266.6 |
| Q1 FY2026 | Mar 31, 2026 | 104.6% | +119.8 |
| Q4 FY2025 | Dec 31, 2025 | 35.6% | +332.4 |
| Q3 FY2025 | Sep 30, 2025 | -2.1% | +897.1 |
| Q2 FY2025 | Jun 30, 2025 | 288.7% | +736.5 |
| Q1 FY2025 | Mar 31, 2025 | -15.2% | +470.1 |
| Q4 FY2024 | Dec 31, 2024 | -296.8% | −142.8 |
| Q3 FY2024 | Sep 30, 2024 | -899.2% | −541.1 |
| Q2 FY2024 | Jun 30, 2024 | -447.9% | −417.5 |
| Q1 FY2024 | Mar 31, 2024 | -485.3% | −69.2 |
| Q4 FY2023 | Dec 31, 2023 | -154.0% | −438.3 |
| Q3 FY2023 | Sep 30, 2023 | -358.1% | −127.9 |
| Q2 FY2023 | Jun 30, 2023 | -30.4% | +1819.0 |
| Q1 FY2023 | Mar 31, 2023 | -416.2% | −369.1 |
| Q4 FY2022 | Dec 31, 2022 | 284.4% | +389.1 |
| Q3 FY2022 | Sep 30, 2022 | -230.2% | −140.7 |
| Q2 FY2022 | Jun 30, 2022 | -1849.4% | −1901.1 |
| Q1 FY2022 | Mar 31, 2022 | -47.0% | +38.0 |
| Q4 FY2021 | Dec 31, 2021 | -104.7% | +100.6 |
| Q3 FY2021 | Sep 30, 2021 | -89.5% | +66.8 |
| Q2 FY2021 | Jun 30, 2021 | 51.8% | +39.3 |
| Q1 FY2021 | Mar 31, 2021 | -85.0% | +190.5 |
| Q4 FY2020 | Dec 31, 2020 | -205.2% | +233.5 |
| Q3 FY2020 | Sep 30, 2020 | -156.3% | −183.0 |
| Q2 FY2020 | Jun 30, 2020 | 12.4% | – |
| Q1 FY2020 | Mar 31, 2020 | -275.4% | – |
| Q4 FY2019 | Dec 31, 2019 | -438.7% | – |
| Q3 FY2019 | Sep 30, 2019 | 26.7% | – |
See a number that looks wrong?